

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re U.S. Patent Application of :  
Peter David Davis :  
Application No.: Not Yet Assigned :  
Filed: July 3, 2003 :

Title: BENZIMIDAZOLE VASCULAR DAMAGING AGENTS

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT UNDER**  
**37 C.F.R. § 1.56, § 1.97(b)(3) AND § 1.98**

In compliance with the duty of disclosure under 37 C.F.R. § 1.56 and in accordance with the practice under 37 C.F.R. § 1.97 (b)(3) and § 1.98, Applicants bring to the attention of the Examiner the documents listed on the attached Form PTO/SB/08A. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the documents were previously submitted in Application No. 09/889,061, filed October 22, 2001 or cited in an Office Action, from which this application claims priority under 35 U.S.C. § 120. Accordingly, no copies are being provided herewith.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each, any, or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the present application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents. Further, Applicants reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied as prior art against the claims of the present application.

**CONCLUSION**

It is respectfully requested that the attached information be considered by the Examiner and that a copy of the attached Form PTO/SB/08A be returned indicating that such information has been considered.

Applicants' undersigned attorney may be reached in our Washington, D.C. office by telephone at (202) 625-3500. All correspondence should continue to be directed to our address given below.

**AUTHORIZATION**

Applicants believe there is no fee due in connection with this filing as this Information Disclosure Statement is being filed prior to any Office Action on the merits in this matter. However, to the extent required, the Commissioner is hereby authorized to charge any fees due in connection with this filing to Deposit Account 50-1710 or credit any overpayment to same.

Respectfully submitted,



Robert W. Hahl, PH.D.  
Registration No. 33,893  
Gilberto M. Villacorta, PH.D.  
Registration No. 34,038

Patent Administrator  
KATTEN MUCHIN ZAVIS ROSENMAN  
525 West Monroe Street, Suite 1600  
Chicago, Illinois 60661-3693  
Facsimile: (312) 902-1061

Dated: July 3, 2003

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Substitute for form 1449/PTO</b>		<b>Citation if Known</b>		
		Application Number		Not Yet Assigned		
		Filing Date		July 3, 2003		
		First Named Inventor		peter David Daivs		
		Art Unit		Not Yet Assigned		
		Examiner Name		Not Yet Assigned		
Sheet	2	of	3	Attorney Docket Number		215233-00107

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Kruse, L.I., et al., "Synthesis, Tubulin Binding, Antineoplastic evaluation, and Structure-Activity Relationship of Oncodazole Analogues," Journal of Medicinal Chemistry,, Vol. 32, No. 2, Feb. 1989, pp. 409-17, XP002142971	
		Lacey, E., et al., "Activity of Benzimidazole Carbamates Against L1210 mouse Leukaemia cells: Correlation with in Vitro Tubulin Polymerization assay," Biochemical Pharmacology, vol. 34, no. 19, 1985, pp. 3603-3605, XP002056333.	
		Chemical Abstract of de Brabander, M.J., et al., "The effects of methyl 5-(2-thienylcarbonyl)-1H-benzimidazol-2-yl Carbamate, (R 17934: NSC 238159), a new synthetic antitumor drug interfering with microtubules, on mammalian cells cultured in vitro," p. 26; XP002143095, cited in the application abstract & Cancer Res., vol. 36, no. 3, 1976, pp. 905-16, Chemical Abstract, vol. 84, no. 21.	
		Khan, A.M. et al., "Studies on enteric anthelmintics: Impact of single point structural change on the activity profile," Zeitschrift Fur Naturforschung, B, vol. 43, no. 2, Feb. 1988, pp. 233-7	
		Raeymaekers, A.H.M., et al., "Synthesis and Anthelmintic Activity of Alkyl-(5-acyl-1H-benzimidazol-2yl) carbamates," Arzneimittel-Forschung, vol. 28 (I), no. 4, 1978, pp. 586-94, XP002142973.	
		Abuzar, S., et al., "Synthesis and anthelmintic activity of 2,2'-disubstitued 5,5-dibenzimidazolylsulfides and sulfones," Arzneimittel-forschung, vol. 36 (I), no. 3, March 1986, pp. 416-9, XP002142974.	
		Database Crossfire "Online", Beilstein Institut zur Foerderung der Chemischen Wissenschaften; XP 002142975, Beilstein Registry no. 4595458 & Indian J. Chem. Sect. B, vol. 19, no. 7, 1980, pp.536-8.	
		Database Crossfire "Online" Beilstein Institut zur Foerderung der Chemischen Wissenschaften; XP 002142976, Beilstein Registry No. 5651135 & Indian J. Chem. Sect. B, vol., 24, 1985, pp. 754-60.	
		Database Crossfire "Online" Beilstein Institut zur Foerderung der Chemischen Wissenschaften; XP 002142977, Beilstein Registry No. 5622648 & Indian J. Chem. Sect. B, vol., 24, 1985, pp. 747-53.	
		Database Crossfire "Online" Beilstein Institut zur Foerderung der Chemischen Wissenschaften; XP 002142978, Beilstein Registry No. 5669479, 5670801, 5667941, 5667940, 5665325 & Indian J. Chem. Sect. B, vol., 24, 1985, pp. 730-2.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	Not Yet Assigned		
		Filing Date	July 3, 2003		
		First Named Inventor	Peter David Davis		
		Art Unit	Not Yet Assigned		
		Examiner Name	Not Yet Assigned		
Sheet	3	of	3	Attorney Docket Number	215233-00107

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Database Crossfire "Online" Beilstein Institut zur Foerderung der Chemischen Wissenschaften; XP 002142978, Beilstein Registry No. 4615289, 4609187, & Indian J. Chem. Sect. B, vol., 23, no. 12, 1984, pp. 1274-8	
		Database Crossfire "Online" Beilstein Institut zur Foerderung der Chemischen Wissenschaften; XP 002142980, Beilstein Registry No. 6009722, 6007941, 6007769 & Indian J. Chem. Sect. B, vol., 24, 1985, pp. 178-81.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(Use as many sheets as necessary)*

**Complete if Known**

Application Number	Not Yet Assigned
Filing Date	July 3, 2003
First Named Inventor	Peter David Davis
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	215233-00107

Sheet	1	of	3
-------	---	----	---

## U. S. PATENT DOCUMENTS

[illegible]

**FOREIGN PATENT DOCUMENTS**

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> *Number <sup>4</sup> *Kind Code <sup>5</sup> (if known)				
		DE 2164690A	07/12/73	Farbwerke Hoechst AG		
		DE 2332343A	01/16/75	Farbwerke Hoechst AG		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.